Scarica l'app Stockscreener
9.59
1.70%
0.16
Dopo l'orario di chiusura:
9.62
0.03
+0.31%
Adicet Bio Inc Borsa (ACET) Ultime notizie
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? - Yahoo Finance
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Upgraded to Strong-Buy at Jefferies Financial Group - MarketBeat
A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC and Prepares Prula-Cel Data Release - Kalkine Media
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC, Prula-cel Data Expected in September 2026 - Kalkine Media
Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat
Adicet Bio advances CAR-T programs and clinical pipeline - grafa.com
Adicet Bio completes prula-cel Phase 1 SLE analysis - TipRanks
The final patient visit is complete in a lupus cell-therapy study. Adicet Bio expects results from 22 patients in September. - Stock Titan
Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan
Adicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street Zen - MarketBeat
Press Release Service: Adicet Bio Announces FDA Clearance of IND Application for ADI-212 - CRISPR Medicine News
Adicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancer - marketscreener.com
Adicet Bio receives FDA clearance for prostate cancer trial - Investing.com
Here's Why You Should Add ACET Stock to Your Portfolio Now - Yahoo Finance
Adicet (ACET) Trading: Adds 0.32% to Close at $9.41 in the Current Update; Key Range - vinanet.vn
ETFs Investing in Adicet Bio Inc Stocks - TradingView
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
ACET Q2 2026 Earnings: Narrower-Than-Expected Loss of $1.99 Per Share Buoys SharesSegment Revenue Breakdown - vinanet.vn
RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker - Stock Titan
Adicet Bio (ACET) - Zacks Investment Research
Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET) - Seeking Alpha
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Zacks Investment Research
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsETF Flow - Vinanet
HC Wainwright Has Strong Estimate for Adicet Bio Q3 Earnings - MarketBeat
Adicet Bio at Canaccord Genuity: lupus data drives next step By Investing.com - Investing.com Canada
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy - MarketBeat
All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy - newsbreak.com
H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $27 - Moomoo
JonesTrading Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Price to sales forward of Adicet Bio, Inc. – NASDAQ:ACET - TradingView
Adicet Bio Inc (ACET) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Press Release Service: Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates - CRISPR Medicine News
Guggenheim cuts Adicet Bio stock price target to $90 on cash position - Investing.com UK
CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adicet Bio, Inc. Stock 12‑Month Price Target Cut to $34.4, Implies 276% Upside - TradingView
ADICET BIO Q2 NET INCOME USD -21.358 MILLION - Moomoo
ADICET Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Adicet Bio (NASDAQ:ACET) Posts Earnings Results, Misses Estimates By $0.30 EPS - MarketBeat
Adicet Bio Q2 net loss narrows - TradingView
Adicet Bio reports Q2 2026 net loss $21.4M; cash runway into H2 2027, clinical updates planned - TradingView
Adicet Bio, Inc. 2Q 2026: Revenue $0 Net loss $(21.4)M, EPS $(1.99) — 10-Q Summary - TradingView
ACET: Q2 2026 net loss narrowed 32% year-over-year; cash runway extends into H2 2027 - TradingView
BRIEF-Adicet Bio Q2 Basic EPS USD -1.99 - TradingView
ACET Q2'26 Earnings: EPS estimate is (1.69) USD - tradingview.com
More Than Two Decades at Johnson & Johnson: Lipocine's New Director - stocktitan.net
Adicet Bio Inc expected to post a loss of $2.03 a shareEarnings Preview - TradingView
ACET Q1 2026 Earnings: Narrower Loss Beats Estimates by 40.74% as Clinical Pipeline AdvancesConsensus Miss Rate - vinanet.vn
Adicet Bio Inc Actuals & Estimates (NASDAQ:ACET) - TradingView
Adicet Bio (NASDAQ:ACET) Share Price Passes Above 200 Day Moving AverageTime to Sell? - MarketBeat
Adicet Bio, Inc. Revenue Breakdown – NASDAQ:ACET - TradingView
Adicet Bio Inc (ACET) Balance Sheet - TradingKey
Adicet Bio Inc (ACET) Cash Flow - TradingKey
Adicet Bio: A 400% Upside Bet on Gamma Delta T-Cell Data - Kavout | AI
Adicet Bio Inc Revenue Breakdown – TRADEGATE:1IJ - TradingView
Adicet Bio Inc (ACET) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Adicet Bio Inc (ACET) Income Statement - TradingKey
Adicet Bio Inc (ACET) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Adicet Bio Inc (ACET) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Adicet Bio Inc (ACET) Valuation: PE, PB & Fair Value Analysis - TradingKey
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):